Skip to main content
Year archive

FARON PHARMACEUTICALS OY — 2026 filings

All 41 regulatory filings released by FARON PHARMACEUTICALS OY (FARN) in 2026, sourced directly from the official regulator.

41 Filings
2026 Period
2026 filings (41)
Filing Released Lang
Faron to present new BEXMAB translational and clinical data in HR-MDS at EHA 2026
Regulatory Filings
2026-05-13 English
Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service
Regulatory Filings
2026-05-06 English
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Regulatory Filings
2026-05-05 English
Faron Pharmaceuticals Ltd: Directorate Appointment
Regulatory Filings
2026-05-05 English
Faron Pharmaceuticals Ltd: Results of the Annual General Meeting
AGM Information
2026-05-04 English
Faron Pharmaceuticals Ltd: Issuance of warrants
Share Issue/Capital Change
2026-04-30 English
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Major Shareholding Notification
2026-04-22 English
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Major Shareholding Notification
2026-04-20 English
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Major Shareholding Notification
2026-04-20 English
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
Share Issue/Capital Change
2026-04-13 English
NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement
2026-04-10 English
Faron Pharmaceuticals Ltd: New shares registered with Finnish Trade Register
Share Issue/Capital Change
2026-04-10 English
Faron publishes final results of its EUR 40.1 million rights issue
Capital/Financing Update
2026-04-09 English
Inside Information: Faron publishes preliminary results of its successful rights issue
Capital/Financing Update
2026-04-08 English
Faron Pharmaceuticals Ltd: Director Dealing
Director's Dealing
2026-03-31 English
Faron Pharmaceuticals Ltd: Faron appoints new CTO to strengthen late-stage development activities
Board/Management Information
2026-03-26 English
Faron Pharmaceuticals Ltd: Director Dealing
Director's Dealing
2026-03-25 English
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Major Shareholding Notification
2026-03-24 English
Faron Pharmaceuticals Ltd: Director Dealing
Director's Dealing
2026-03-19 English
Faron Pharmaceuticals Ltd: Director Dealing
Director's Dealing
2026-03-19 English
Faron Pharmaceuticals Ltd: Director Dealing
Director's Dealing
2026-03-19 English
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Major Shareholding Notification
2026-03-12 English
The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus
Capital/Financing Update
2026-03-11 English
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Major Shareholding Notification
2026-03-11 English
Inside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway
Capital/Financing Update
2026-03-10 English
Update to Faron’s Financial Calendar and date of the Annual General Meeting in 2026
Report Publication Announcement
2026-03-09 English
Correction: Faron Pharmaceuticals Ltd’s Annual Report 2025 published
Report Publication Announcement
2026-03-04 English
Faron Pharmaceuticals Ltd’s Annual Report 2025 published
Report Publication Announcement
2026-03-04 English
Faron’s Financial Statements Release 1 January to 31 December 2025
Annual Report FY 2025
2026-03-04 English
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting
Declaration of Voting Results & Voting Rights Announcements
2026-03-02 English
Faron and City of Hope in process of developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS
Regulatory Filings
2026-03-02 English
Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026
Regulatory Filings
2026-02-23 English
Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML
Regulatory Filings
2026-02-19 English
Faron Pharmaceuticals Ltd: NOTICE TO THE EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement
2026-02-09 English
Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones
Capital/Financing Update
2026-02-09 English
Faron Pharmaceuticals Ltd: Registration of New Shares
Share Issue/Capital Change
2026-02-03 English
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds
Share Issue/Capital Change
2026-02-03 English
New review published in Immunotherapy highlights the potential for Clever-1 inhibition with bexmarilimab to become the cornerstone of next-generation, multi-indication cancer immunotherapy
Regulatory Filings
2026-01-29 English
Faron Expands Bexmarilimab Program in Solid Tumors with a Randomized Phase I/II BEXAR IIT in Metastatic Soft-Tissue Sarcoma
Regulatory Filings
2026-01-27 English
Faron Pharmaceuticals Ltd: PDMR Dealing
Director's Dealing
2026-01-13 English
Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds
Share Issue/Capital Change
2026-01-08 English